3 Catalysts That Could Ignite AXTI Stock on Oct. 29 (And 1 Huge Risk)

AXT reports Q3 results on Oct. 29 after shares fell 28.05% over the past month; management’s forecast is $66 million in revenue and non-GAAP EPS of $0.30–$0.32. Catalysts include an InP backlog of well over $100 million, capacity expansion, and potential margin gains, while delayed China export permits could push revenue out. Last quarter revenue was a record $47.6 million, and gross margin rose to 44.9% from 8.0% a year earlier.

Analysis

AXTI is now an execution-and-permit-risk story, not simply an AI demand proxy. The key distinction is between customer demand and revenue that can ship: delayed Chinese export permits could leave backlog intact while pushing reported revenue, cash conversion and capacity utilization out. That makes the inventory build a more important signal than backlog alone. Verify inventory aging, receivables and operating cash flow; the subsidiary redemption right also warrants clarification on who funds any redemption and whether it constrains parent liquidity.

The near-term bar is elevated: guidance is already close to consensus, and the prior earnings-day reaction is not a reliable template after a sharp year-to-date rerating. A strong quarter may be insufficient if management cannot demonstrate permit clearance and credible Q4 conversion. Conversely, margin improvement alongside stable inventory and cash conversion would support the view that pricing and utilization are translating into economics, not just shipments pulled forward.

For COHR and Lumentum, secured InP supply could reduce component bottlenecks and support their own delivery schedules; it does not establish a material earnings uplift without evidence of their exposure and supply alternatives. Contrarian angle: the selloff may have discounted a demand break when the binding constraint is permits—but backlog is not a hedge against indefinite delays. The 6–18 month upside depends on capacity arriving on schedule without worsening working capital or diluting margins.

Key Decisions for Investors

• Avoid initiating a full-size AXTI long before the Oct. 29 report; the event is asymmetric after the large rerating, and guidance is already embedded in near-term estimates. Reassess after the release and call.
• For a post-report long, require more than an EPS beat: look for shipment/permit evidence, a credible Q4 outlook, improving gross margin, and inventory and cash conversion that do not deteriorate. Stage entry only if these confirm together.
• If permits stall, Q4 visibility weakens, or inventory rises without corresponding shipments, treat backlog as lower-quality and reduce or avoid AXTI exposure. Clarify the Tongmei redemption funding and parent-level liquidity before assigning additional balance-sheet risk.
• Do not use COHR or Lumentum as automatic hedges: their potential benefit from supply continuity is conditional, while customer concentration and alternative sourcing are unquantified. Monitor their commentary for evidence of shipment constraints or supplier diversification.